Assembly Biosciences Inc (ASMB) Actualités

Form SC 13D - General statement of acquisition of beneficial ownership

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

––Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with...

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in...

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry...

Form 3 - Initial statement of beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]